Xianhui Qin1, Jianping Li1, J David Spence1, Yan Zhang1, Youbao Li1, Xiaobin Wang1, Binyan Wang1, Ningling Sun1, Fang Chen1, Jingxuan Guo1, Delu Yin1, Liming Sun1, Genfu Tang1, Mingli He1, Jia Fu1, Yefeng Cai1, Xiuli Shi1, Ping Ye1, Hong Chen1, Shuiping Zhao1, Mao Chen1, Chuanyu Gao1, Xiangqing Kong1, Fan Fan Hou1, Yining Huang2, Yong Huo1. 1. From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.). 2. From the Renal Division, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Guangzhou, China (X.Q., Y.L., B.W., F.F.H.); Department of Cardiology (J.L., Y.Z., Y. Huo) and Department of Neurology (Y. Huang), Peking University First Hospital, Beijing, China; Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, London, Canada (J.D.S.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (X.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S., H.C.); Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (F.C.); Department of Cardiology, Peking University Third Hospital, Beijing, China (J.G.); Department of Cardiology, First People's Hospital, Lianyungang, China (D.Y.); Department of Cardiology, Second People's Hospital, Lianyungang, China (L.S.); Institute for Biomedicine, School of Health Administration (G.T.) and Department of Neurology, First Affiliated Hospital (J.F., X.S.), Anhui Medical University, Hefei, China; Department of Neurology, First People's Hospital, Lianyungang, China (M.H.); Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Y.C.); Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, China (P.Y.); Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China (S.Z.); Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China (M.C.); Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China (C.G.); and Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China (X.K.). ynhuang@sina.com huoyong@263.net.cn.
Abstract
BACKGROUND AND PURPOSE: We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial. METHODS:A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke. RESULTS: The median treatment duration was 4.5 years. For participants not receiving folic acid treatment (enalapril-only group), high total cholesterol (≥200 mg/dL) was an independent predictor of first stroke when compared with low total cholesterol (<200 mg/dL; 4.0% versus 2.6%; hazard ratio, 1.52; 95% confidence interval, 1.18-1.97; P=0.001). Folic acid supplementation significantly reduced the risk of first stroke among participants with high total cholesterol (4.0% in the enalapril-only group versus 2.7% in the enalapril-folic acid group; hazard ratio, 0.69; 95% confidence interval, 0.56-0.84; P<0.001; number needed to treat, 78; 95% confidence interval, 52-158), independent of baseline folate levels and other important covariates. By contrast, among participants with low total cholesterol, the risk of stroke was 2.6% in the enalapril-only group versus 2.5% in the enalapril-folic acid group (hazard ratio, 1.00; 95% confidence interval, 0.75-1.30; P=0.982). The effect was greater among participants with elevated total cholesterol (P for interaction=0.024). CONCLUSIONS:Elevated total cholesterol levels may modify the benefits of folic acid therapy on first stroke. Folic acid supplementation reduced the risk of first stroke associated with elevated total cholesterol by 31% among hypertensive adults without a history of major cardiovascular diseases. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.
RCT Entities:
BACKGROUND AND PURPOSE: We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial. METHODS: A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke. RESULTS: The median treatment duration was 4.5 years. For participants not receiving folic acid treatment (enalapril-only group), high total cholesterol (≥200 mg/dL) was an independent predictor of first stroke when compared with low total cholesterol (<200 mg/dL; 4.0% versus 2.6%; hazard ratio, 1.52; 95% confidence interval, 1.18-1.97; P=0.001). Folic acid supplementation significantly reduced the risk of first stroke among participants with high total cholesterol (4.0% in the enalapril-only group versus 2.7% in the enalapril-folic acid group; hazard ratio, 0.69; 95% confidence interval, 0.56-0.84; P<0.001; number needed to treat, 78; 95% confidence interval, 52-158), independent of baseline folate levels and other important covariates. By contrast, among participants with low total cholesterol, the risk of stroke was 2.6% in the enalapril-only group versus 2.5% in the enalapril-folic acid group (hazard ratio, 1.00; 95% confidence interval, 0.75-1.30; P=0.982). The effect was greater among participants with elevated total cholesterol (P for interaction=0.024). CONCLUSIONS: Elevated total cholesterol levels may modify the benefits of folic acid therapy on first stroke. Folic acid supplementation reduced the risk of first stroke associated with elevated total cholesterol by 31% among hypertensive adults without a history of major cardiovascular diseases. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.